PDT is a clinically useful cancer therapy. Its further improvement requires the rational design of nextgeneration single and multifunctional PS which may be combined with secondary agents to enhance efficacy and selectivity. The secondary agents may influence tissue and cell distribution and pharmacokinetics (PK) of the PS. The studies described in this Core are crucial to determine the appropriate dosing schedules and treatment regimens of the modified PS for the best outcome and the clinical advancement of PDT.
Showing the most recent 10 out of 167 publications